Comparative Pharmacology
Head-to-head clinical analysis: TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT versus TECHNETIUM TC 99M TSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT versus TECHNETIUM TC 99M TSC.
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT vs TECHNETIUM TC 99M TSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium Tc 99m albumin aggregated is a radiopharmaceutical that localizes in the pulmonary capillary bed by capillary blockade, allowing for lung perfusion imaging. The aggregated albumin particles are trapped in the pulmonary capillaries, and the Tc 99m emits gamma radiation detectable by gamma cameras.
Technetium Tc 99m TSC is a radiopharmaceutical that binds to activated leukocytes, primarily neutrophils, via interaction with integrin receptors (e.g., CD11b/CD18), allowing imaging of inflammation and infection.
1-4 mCi (37-148 MBq) intravenous injection for lung perfusion imaging. Single dose per imaging session.
1-10 mCi (37-370 MBq) intravenously as a single dose for imaging studies; dose depends on indication and imaging protocol.
None Documented
None Documented
Physical half-life of Tc-99m is 6.02 hours; biological half-life of aggregated albumin in lungs is 2-4 hours due to enzymatic degradation and clearance.
Terminal half-life approximately 6 hours; allows for same-day imaging but requires prompt scanning due to radionuclide decay.
Renal: 30-40% within 24 hours (free pertechnetate); fecal: <1% (minor); remainder accumulated in reticuloendothelial system with slow release.
Renal: ~50% excreted unchanged in urine within 24 hours; remainder eliminated via hepatobiliary system into feces.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical